Triumph Capital Management’s Sana Biotechnology SANA Stock Holding History

Triumph Capital Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.49K	Hold	1,000	–	–	﹤0.01%	1468
2026 Q1	$2.88K	Hold	1,000	–	–	﹤0.01%	1471
2025 Q4	$4.07K	Buy	+1,000	New	+$4.48K	﹤0.01%	1317
2025 Q3	–	Sell	-14,675	Closed	-$40.1K	–	337
2025 Q2	$40.1K	Sell	14,675 -7,000	-32%	-$14.4K	0.01%	286
2025 Q1	$36.4K	Buy	+21,675	New	+$60.6K	0.01%	276

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Triumph Capital Management's SANA Position: Q2 2026 in Review

Triumph Capital Management held its Sana Biotechnology (SANA) position steady in Q2 2026 at 1,000 shares worth $3.49K. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

Triumph Capital Management first reported a position in SANA in Q1 2025 and has held it in 5 quarters since. The position peaked at $40.1K in Q2 2025. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Triumph Capital Management held 1,000 shares of Sana Biotechnology worth $3.49K as of Q2 2026.
Triumph Capital Management left its Sana Biotechnology share count unchanged in Q2 2026.
Sana Biotechnology made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1468 holding.
Triumph Capital Management first reported a position in Sana Biotechnology in Q1 2025 and has held it in 5 quarters since.
Triumph Capital Management's Sana Biotechnology position peaked at $40.1K in Q2 2025.
211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.